Hematologists near Paramus, NJ

Biography: Dr. Justine Kahn is a Pediatric Oncologist and a clinical investigator specializing in survival outcomes, cancer care delivery, and health equity in children and adolescent/young adults (AYA) with Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Dr. Kahn received her MD from the Icahn School of Medicine at Mount Sinai in New York and completed her Pediatric Residency at Mount Sinai Kravis Children's Hospital in New York. Dr. Kahn completed her Clinical Fellowship in Pediatric Hematology/Oncology at Columbia University Medical Center. While in residency, Dr. Kahn was elected to Alpha Omega Alpha, the national medical honor society which recognizes high educational achievement. During her fellowship, Dr. Kahn served as a Postdoctoral Research Fellow in Cancer-Related Population Sciences supported by the National Cancer Institute for her work in cancer care delivery, health equity, and health outcomes research. Upon graduation from fellowship, Dr. Kahn joined the Pediatric Hematology/Oncology Division at Columbia University Medical Center as an Oncology Instructor and Attending Physician in 2016. She is currently involved in patient care, clinical trials research, and health outcomes research. In June of 2018, Dr. Kahn obtained a Master of Science in Patient Oriented Research at the Columbia Mailman School of Public Health. In July of 2018 she became an Assistant Professor of Pediatrics in the Division of Pediatric Hematology/Oncology/Stem Cell Transplantation. Dr. Kahn is actively conducting research through studies developed in the Dana-Farber Cancer Institute (DFCI) ALL Consortium, the Children's Oncology Group (COG), and at Columbia University. Columbia boasts a strong commitment to health disparities research in one of the most diverse patient populations in the United States. Dr. Kahn has chosen to focus her research efforts on underserved populations because studies suggest that poor access-to-care, low health literacy, and financial stress can all negatively impact survival in children and AYAs with cancer. Dr. Kahn is supported in part by the Lymphoma Research Foundation and recently received an institutional Career Development Award for her ongoing work on survival disparities in children and AYAs with Hodgkin lymphoma. She serves as CUMC site Principal Investigator for the DFCI ALL Consortium.

Biography: Manuela Orjuela-Grimm is a molecular epidemiologist and pediatric oncologist whose research focuses on vulnerability (including social) to environmental exposures, gene-nutrient/ environment interactions during windows of susceptibility such as pregnancy, early childhood, adolescence and the development of later genetic and epigenetic changes contributing to poorer health outcomes in childhood and adolescence. She leads EpiRbMx, a long-standing case control/ case series study examining exposure to methyl donors, folate pathway metabolism and risk for retinoblastoma in collaboration with a multidisciplinary team of investigators including the Hospital Infantil de Mexico, the Hospital de Pediatria at the Instituto Mexicano de Seguro Social (IMSS), the Instituto Nacional de Salud Publica (INSP), and the University of Toronto. In collaboration with INSP researchers, Dr. Orjuela is involved in multiple studies examining the intersection between food security, folate-related dietary intake, dietary diversity and environmental exposures in central Mexico, and in immigrants in New York. Interests: social contributors to dietary exposures, gene-nutrient interactions; one carbon donor metabolism; methylation; nutrient and environmental exposures during early life and later genetic and epigenetic effects; dietary assessment in Mexico, in populations on the move in Latin America; effects of acculturation and early life migration on nutrient/ environmental exposures in US Latinos.

Biography: Monica Bhatia, MD specializes in the care of children with noncancerous blood disorders who may benefit from bone marrow transplantation, especially sickle cell anemia. She and her colleagues are working to reduce the toxicity (side effects) and complications of this treatment without compromising its effectiveness, and to make it available to more patients. The field of pediatric hematology brings with it many intellectual challenges, and bone marrow transplantation in particular is especially dynamic. Dr. Bhatia has the opportunity to provide care for the sickest children, potentially curing their disease. She builds strong relationships with her patients and their families that last for years. It is inspiring for her to see young patients grow up to lead healthy, productive lives. NewYork-Presbyterian/Morgan Stanley Children's Hospital has a robust program for bone marrow transplantation for sickle cell anemia - the only cure for this disease. Dr. Bhatia and her team have witnessed remarkable results among children who are cured with bone marrow transplantation and spared from the potentially life-threatening complications of sickle cell disease. Yet despite the advances made, only 15 percent of patients with sickle cell disease have a matched sibling bone marrow donor. Therefore, Dr. Bhatia and her team conduct research to evaluate a procedure called "CD34-selected stem cell transplantation" to remove T-cells from donor bone marrow for patients without a matched sibling donor. This approach reduces the risk of graft-versus-host disease (GVHD), a potential complication of bone marrow transplantation in which T-cells from the donor attack the tissue of the recipient. This approach to harnessing stem cells could potentially make bone marrow transplantation a safer, effective option for many patients who are seeking a cure for sickle cell disease. Dr. Bhatia and her colleagues are currently assessing reduced-intensity transplantation, which uses lower doses of chemotherapy to decrease the risk of side effects and long-term complications without lowering the effectiveness of treatment. She is also interested in looking for ways to further improve the quality of life of patients who have had a bone marrow transplant in addition to fertility preservation.

Biography: Dr. Dominder Kaur received her medical degree from Maharashtra University of Health Sciences, Nashik in India and completed her pediatric residency at Northwell Health Staten Island University Hospital in New York. She trained in pediatric hematology-oncology at the Mayo Clinic in Minnesota while also receiving a Masters in Clinical and Translational Science from the Mayo School of Graduate Medical Education. She received further specialized training as the Joan Wallick Pediatric Hemostasis Thrombosis fellow at the Nationwide Children's Hospital. She joined as faculty at Columbia University/Columbia Presbyterian Medical Center in December 2018 as an Assistant Professor in Pediatrics. Dr. Kaur was the recipient of the Thrombosis & Hemostasis Societies of North America (THSNA) 2018 Young Investigator Award. Her research focus so far has been on bleeding and thrombotic complications stem cell transplant recipients. She is currently working towards improving screening methodology and approaches to bleeding disorder evaluation in children. She is passionate about improving hematological services for young adults, especially young women with possible bleeding disorders. In collaboration with Adolescent Medicine team, Dr. Kaur staffs the Girls & Young-women's Bleeding Issues Clinic (GYBiC). This clinic is one of only two such centers in New York metropolitan area and offers hematological and adolescent medicine specialty consultations and evaluations in one comprehensive visit. The Girls & Young-women's Bleeding Issues Clinic specializes in the diagnosis and treatment of bleeding (like heavy periods/menorrhagia) and clotting disorders (thrombophilia) and accompanying health issues in young women of reproductive age.

Biography: Dr. Stergios Zacharoulis, MD is a Radiation Oncology Specialist who practices in New York, NY. He is 55 years old and has been practicing for 30 years. Dr. Stergios Zacharoulis, MD is affiliated with Newyork-Presbyterian/Columbia University Medical Center and Newyork-Presbyterian/Morgan Stanley Children's Hospital.

Biography: Originally from Columbus, OH, SunilIyercompleted his undergraduate studies at Washington University in St. Louis. He then completed his medical education and training at the University of Miami, where he served as chief hematology/oncology fellow. He has a strong interest in leukemia, particularly in the genomics and treatment of acute lymphoblastic leukemia.

Biography: Dr. Tamna Wangjam, MD is a Hematology Specialist who practices in New York, NY. She is 39 years old and has been practicing for 16 years. Dr. Tamna Wangjam, MD is affiliated with Newyork-Presbyterian/Columbia University Medical Center.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Biography: Dr. Sathe completed her Residency in Internal Medicine at NYP/Weill Cornell and is a graduate of Rutgers-New Jersey Medical School. She also holds a JD from Columbia Law School. Her research focuses on improving cancer care delivery and reducing disparities in treatment and outcomes.

Biography: Dr. Andrew H. Lipsky is an Assistant Professor of Medicine at the Columbia University Medical Center. He specializes in caring for adult patients with hematologic malignancies, including chronic lymphocytic leukemia (CLL) and lymphoma.Dr. Lipsky's research focuses on cancer genomics and new treatments for CLL. He has a special interest in using the latest bioinformatics techniques to study how cancer cells change and adapt during treatment. Utilizing these genomic insights, he hopes to better inform clinical trials and hasten the development of innovative therapies for patients with hematologic malignancies.Dr. Lipsky earned his medical degree from Rutgers - Robert Wood Johnson Medical School. He completed internship and residency in internal medicine at Montefiore - Albert Einstein College of Medicine. He completed fellowship training in Hematology and Medical Oncology at New York Presbyterian Hospital Weill Cornell Medical College, with an additional sub-fellowship in the clinical care of CLL and lymphoma. He also completed a postdoctoral research fellowship in lymphoma genomics and bioinformatics as part of the Molecular and Translation Oncology Research (MTOR) training program.

Biography: Dr. Henick is a medical oncologist specializing in the care of patients with malignancies of the aerodigestive tract.As the Associate Director of Experimental Therapeutics and Director of Translational Research in Aerodigestive Cancers in Medical Oncology, Dr. Henick's clinical care and research are aligned to improve the effectiveness of, and limit toxicity from, emerging cancer treatments. These effortsentail clinical trials that Dr. Henick has written and leads to study novel therapeutic approaches and to reduce steroid dependence among patients experiencing adverse events fromimmunotherapy.

Biography: Dr. Hua-Jay "Jeff" Cherng is an assistant professor of medicine in the lymphoma program in the Division of Hematology and Oncology. He earned his medical degree from Case Western Reserve University and completed internal medicine residency at the Hospital of the University of Pennsylvania. He subsequently trained at MD Anderson Cancer Center for his hematology and oncology fellowship. He is board certified in Internal Medicine, Hematology and Medical Oncology. Dr. Cherng is a clinical investigator who researches non-invasive response assessment tools such as biomarkers and imaging to predict outcomes of lymphoma patients. His focus is on circulating tumor DNA (ctDNA), fragments of genetic material shed by lymphomas that can be sequenced and tracked to measure molecular response and minimal residual disease. His work on ctDNA and PET scans in lymphoma has led to publications in high-impact journals including Blood, Blood Advances, American Journal of Hematology, and British Journal of Haematology. He has earned abstract merit awards from the American Society of Hematology, American Society of Clinical Oncology, and Pan Pacific Lymphoma Conference. His accomplishments during fellowship earned him a Waun Ki Hong Award for Achievement in Clinical Investigation. His research on ctDNA in patients with relapsed lymphoma receiving chimeric antigen receptor T-cell therapy is funded by a Conquer Cancer Young Investigator Award grant. He is a member of Southwestern Oncology Group Lymphoma Working Group and Committee. He was selected to participate in the Academy of Next Wave of Investigators for non-Hodgkin's lymphoma and the American Society of Hematology Clinical Research Training Institute, competitive programs aimed at supporting academic and career development for promising clinical researchers. Dr. Cherng's goal is to design clinical trials with treatment guided by ctDNA; this would allow for treatment de-escalation in good responders to minimize toxicity and escalation in poor responders to maximize chance for durable remissions. Dr. Cherng sees patients with all types of lymphoma with an emphasis on aggressive non-Hodgkin B-cell lymphomas. He treats patients with standard-of-care treatments as well as on clinical trial protocols.